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ABSTRACT 
Peripheral arterial disease is a common health problem that globally affects over 200 
million individuals, and intermittent claudication (IC) is the most common symptomatic 
presentation. The leg symptoms in IC are provoked by walking exercise and can be 
alleviated by medical intervention, exercise training and invasive vascular interventions 
(revascularization). The quality of evidence for invasive treatment is low and the efficacy, 
in terms of patient-oriented endpoints (e.g. health-related quality of life, HRQoL, and 
walking capacity), remains to be established. Appropriate validated instruments for the 
evaluation of HRQoL in IC are scarce, and accurate clinical evaluation of walking 
capacity remains challenging. The main aim of this thesis was to investigate the efficacy 
of a primary invasive versus a primary non-invasive treatment strategy in IC patients 
receiving best medical treatment and a structured non-supervised exercise program. 
Secondary aims were to validate and develop HRQoL instruments in IC, and to study the 
ability of different walk tests to mirror free-living walking capacity and HRQoL.  
The efficacy of revascularization was investigated in two randomized controlled trials 
(study I and V). A disease-specific HRQoL instrument (VascuQoL) was validated within 
a Swedish context in a prospective cohort study (study II), and the feasibility of a short 
version was explored (study III). The correlations of three clinically used walking 
capacity estimates with GPS-assessed “real-life” outdoors walking capacity and HRQoL 
were investigated in another cohort study. 
We found that a primary invasive treatment strategy improved HRQoL (study I) and 
HRQoL and claudication distance (study V) during follow-up. Validity of the Swedish 
version of the VascuQoL was established (study II), and a promising short version 
(VascuQoL-6) could be developed (study III). The six-minutes walk test was shown to 
correlate closely to “real-life” outdoor walking capacity and HRQoL. 
In conclusion, we established that a primary strategy of revascularization, when added to 
best medical treatment and structured non-supervised exercise training, improves quality 
of life and important aspects of walking capacity in patients with intermittent 
claudication. The Swedish version of the VascuQoL is valid in the assessment of HRQoL 
in IC and the VascuQoL-6 holds promise for practical use in routine clinical care. The six-
minutes walk test could be recommended in the clinical evaluation strategy of IC patients.  
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